

Dokumentation einer Behandlungsstatistik gegen Krebs mit Amygdalin (Vitamin B-17)
 Studie aus Japan in den 90iger Jahren!

These are data provided by Dr. Kamataro Sano of Sano Surgical Hospital, 22-4. Aosawa 2
 Chome, Kofu, Japan.

All of the patients have been undergoing Dr. Sano's special treatments in addition to Dr. Goldberg's 10 points therapy, CDA-II, which included urine therapy, diet therapy, large dosage of vitamin C (20-40g/day),

and Vitamin B₁₇ –Amygdalin- (3-12 g/day).

The dosage of CDA-II was 200 c.c.(10g), which was mixed with vitamin C and 500 c.c. of Ringer solution to be administered by i.v. infusion.

In case of capsule, the dosage was 15 capsules a day.

Of 50 patients treated 47 patients were regarded invaluable, who have been treated with CDA-II for more than 4 weeks. In the surgery column O means yes, and x means no.

Summary of Clinical Efficacy of CDA-II Conducted at the First Affiliated Hospital of Anhui Medical University		
<u>Clinical Efficacy</u>	<u>Cases</u>	<u>%</u>
Complete remission	2	6
Partial remission	6	19
Stabile	15	47
Ineffective	9	28

All patients were treated with CDA-II by i.v. infusion only. The dosage was 200cc(10g) per day, which was mixed with 300cc of Ringer solution. Of 47 patients treated 32 patients were considered evaluable for undergoing treatment over 4 weeks. 15 patients gave up treatment for various reasons.

Adverse Effects of CDA-II;G		
<u>Adverse Effects</u>	<u>Cases</u>	<u>%</u>
Venous irritation	7	17
Dizziness	2	5
Abdominal gas	1	2
Fever	2	2
Nausia	1	2

41 cases among 47 cases treated were considered invaluable for undergoing treatment over 3 weeks.

No.	Patient	Sex	Age	Diagnosis	Treatment Period	Symptomatic Improvement	Adverse Effects	Clinical Efficacy
1	§d;³p	male	73	Oesophagus cancer post radiotherapy recurrence	95.10.25-95.11.30	Progressive disease	None	Ineffective
2	÷á;³ææ	male	64	Lung cancer(upper right) metastasized	95.11.7-96.1.2	Slight improvement	None	Stabile

Dokumentation einer Behandlungsstatistik gegen Krebs mit Amygdalin (Vitamin B-17)
 Studie aus Japan in den 90iger Jahren!

				to the subclavian bone				
3	ˆL ₁ ^{3^}	female	58	Cervical cancer metastasized to the vulva and abdominal-vaginal joint	95.10.20-95.12.10	Marked decrease of tumour size and improvement of symptom	Venous irritation	Partial remissions
4	¶ ₁ ³ «H	male	72	Non Hodgkin lymphoma, stage 3	95.11.2-96.4.8	Tumours disappearing, also disappearance of pressure due to tumours, general conditions greatly improved	Dizziness Venous irritation	Complete remission
5	¼B ₁ ³⁰ Ö	male	70	Esophagogastric cancer with wide spread metastasis	95.11.11-95.11.20	Passes away due to massive bleeding	None	----
6	Ä ₁ ³ ˆA	male	50	Malignant lymphoma, stage 4	95.10.25-95.12.6	Progressive disease to end in death	Flush	Ineffective
7	§ö ₁ ³ ¶Í	male	40	Lung cancer, stage 4, metastasized to the spine	95.11.7-95.12.23	General conditions improved	Nausea	Stabile
8	ˆë ₁ ³ µo	male	64	Lung cancer post surgery metastasis to the chest spine	95.11.8-95.11.28	Progressive disease	Fever, dizziness	Ineffective
9	Á ₁ ³ ©M	male	30	Nasopharyngeal carcinoma metastasized to the bone and lung	95.11.21-95.12.19	Progressive disease	None	Ineffective
10	® ₁ ³ ©ü	male	60	Esophagus cancer, post radiotherapy recurrence, metastasized to the lung	96.7.18-96.8.22	Tumour in the lung increasing	None	Ineffective
11	» ₁ ³ Z	male	32	Malignant lymphoma, stage 3	95.11.15-95.12.10	No change	None	----
12	¶ý ₁ ³ ¶	male	78	Prostate cancer metastasized to the bone, stage 4	95.11.25-95.12.4	Patient declines further treatment	None	----
13	±ä ₁ ³ µo	male	67	Esophagus cancer, post radiotherapy recurrence	95.11.20-96.1.2	Stabile and slow improvement	None	Stabile
14	½ ₂ ³ ©¾	male	50	Late stage hepatoma with large volume of ascites fluid	96.1.12-96.3.10	Decrease of ascites fluid and abdominal distension, tumour stabilized	None	Partial remission
15	ˆö ₁ ³ T	male	70	Lung cancer metastasized	96.1.25-96.2.19	Seems to improve the first two weeks,	None	----

Dokumentation einer Behandlungsstatistik gegen Krebs mit Amygdalin (Vitamin B-17)
 Studie aus Japan in den 90iger Jahren!

				outside chest		but deteriorates afterward		
16	lw ₁ ³	male	58	Kidney cancer, post surgery metastasis to the lung	96.4.10-96.5.2	No change	No	----
17	Ꞩð ₁ ³ ꞨÐ	male	72	Lung cancer multiple metastasis to the spine	96.2.2-96.3.4	Stabile but not much improvement	None	Stabile
18	§d ₁ ³ ã	female	60	Late stage hepatoma with ascites	96.7.2-96.7.22	Progressive disease	Venous irritation	----
19	³- ₁ ³ .s	male	46	Lower larynx cancer, post surgery metastasis to the neck	96.7.29-96.8.29	Progressive disease	None	Ineffective
20	Á§ ₁ ³ -u	male	76	Lung cancer(upper left) metastasized to the chest wall	96.3.25-96.5.18 96.10.10-96.11.10	Tumours disappearing, general condition greatly improved, increase of appetite and body weight	Venous irritation	Complete remission
21	´ö ₁ ³ µØ	male	54	Lung cancer, left side, metastasized to the brain	96.2.30-96.3.30	Stabile and slow improvement	Slight venous irritation	Stabile
22	§ð ₁ ³ ^	female	48	Malignant glioma, post surgery metastasis to the lung	96.7.2-96.7.24	No change	None	----
23	½² ₁ ³ ø	male	62	Lung cancer left side, metastasize to the lumbar spine	96.5.22-96.7.2	Progressive disease	Venous irritation	Ineffective
24	¶À ₁ ³	male	62	Esophagus cancer, post surgery metastasis to the liver	96.7.10-96.8.2	No change	None	----
25	»u ₁ ³	male	66	Lung cancer, post surgery wide spread to the chest and brain	96.5.12-96.6.28	Stabile and improving	None	Stabile
26	§ð ₁ ³ »	male	46	Late stage lung cancer with wide spread metastasis	96.10.6-96.11.2	Stabile and improving	Abdominal distention	Stabile
27	¾G ₁ ³ .~	male	56	Esophagus cancer metastasized to the liver	96.11.20-96.12.10	Stabile and slight improvement	None	----
28	¼B ₁ ³ µX	female	70	Lung cancer, left side, metastasized to the lumbar spine	96.11.20-96.12.20	Tumours greatly shrinked, symptom greatly improved	None	Partial remission

Dokumentation einer Behandlungsstatistik gegen Krebs mit Amygdalin (Vitamin B-17)
 Studie aus Japan in den 90iger Jahren!

29	±i _j ³ →Â	male	50	Larynx cancer, post surgery metastasis to the lung	96.11.10-96.12.20	Tumours greatly shrunk, symptom greatly improved	Venous irritation	Partial remission
30	«\i _j ³ °ê	male	47	Colon cancer with wide spread metastasis	96.12.10-96.12.30	Stabile and slight improvement	None	----
31	±i _j ³ °Û	male	74	Esophagus cancer metastasized to the lung	96.12.10.97.1.8	Stabile and improving	None	Stabile
32	§d _j ³ «C	female	42	Cervical cancer with wide spread metastasis	96.11.2-97.1.2	Good symptomatic improvement, becoming more energetic, Tumours stabilized	None	Partial remission
33	¼i _j ³ ½	female	61	Lung cancer metastasized to the liver	96.10.12.96.12.10	Stabile and improving	None	Stabile
34	³\i _j ³	female	20	Brain stem tumour, post radiotherapy recurrence	96.11.10-97.1.2	Stabile, quality of life improved	None	Stabile
35	±i _j ³ !	male	38	Rectal cancer, post surgery wide spread metastasis to the abdominal cavity	96.12.28-97.2.18	Progressive disease	None	Ineffective
36	¼B _j ³ «T	male	54	Lung cancer, stage 4	96.10.15-96.11.27	Stabile and improving	None	Stabile
37	ÃQ _j ³ ¥Á	male	38	Nasopharyngeal carcinoma, post radio therapy metastasis	96.12.20-967.2.5	Stabile and improving	None	Stabile
38	³\i _j ³ ¼y	male	64	Lung cancer(right side), post surgery metastasis	96.11.7-96.12.7	Stabile and improving	None	Stabile
39	¼B _j ³ °Ö	male	56	Stomach cancer metastasized to the liver	96.11.20-96.12.15	Patient declines further treatment	None	----
40	®\i _j ³ ¶³	male	59	Esophagus cancer metastasized to the lung	96.11.31-96.12.14	Patient declines further treatment because of lack of improvement	None	----
41	í _j ³ «T	male	68	Rectal cancer, post surgery recurrence	96.12.8-97.1.20	Decrease of tumour size and pain, increase of appetite	None	Partial remission
42	¶\i _j ³ ^	female	57	Ovarian cancer, post surgery wide spread metastasis	97.1.2-97.1.22	Patient can not afford further treatment	None	----

Dokumentation einer Behandlungsstatistik gegen Krebs mit Amygdalin (Vitamin B-17)
 Studie aus Japan in den 90iger Jahren!

43	1/4i;3®Ä	male	49	Malignant melanoma with wide spread metastasis	96.12.5-97.1.15	Progressive disease	None	Ineffective
44	³£;³¥Í	male	65	Lung and bile duct cancer	96.10.20-96.10.30	Progressive disease	None	----
45	§õ;³-Ã	female	36	Stomach cancer metastasized to the liver, jaundice	96.12.10-96.12.24	Progressive disease	None	----
46	³°;³©¾	male	48	Lung cancer, lower right side	97.1.31-97.3.1	Stabile and improving	None	Stabile
47	©P;³	male	36	Sarcoma of the smooth muscle of the back side of abdominal cavity	97.2.16-97.3.26	Stabile and improving	None	Stabile

Summary of Clinical Efficacy of CDA-II Conducted in Japan

Clinical Efficacy	Anticancer Effect	Symptomatic Improvement	Subtotal	Percentage
Complete remission	Total eradication of Tumours	Dramatic increase of appetite, also dramatic improvement on respiration, pain, and cough	4	%
Partial remission	Decrease of tumour size over 50%	Good appetite, also good improvement on respiration, pain, and cough	16	34%
Imporvement	Decrease of tumour size less than 50%	Recovery pf appetite, also noticeable improvement on respiration, pain, and cough	13	28%
	No change	No significant change of symptoms	8	17%
Progressive	Tumours imcreasing	Worsening to result in death	5	11%
Total			47	100%

All of the patients have been undergoing Dr. Sano's special treatmens in addition to CDA-II, which included urine therapy , diet therapy, large dosage of vitamin C (20-40g/day), and B17 (3-12 g/day). The dosage of CDA-II was 200 c.c.(10g), which was mixed with vitamin C and 500 c.c. of Ringer solution to be administered by i.v. infusion.

In case of capsule, the dosage was 15 capsules a day.

Of 50 patients treated 47 patients were regarded evaluable, who have been treated with CDA-II for more than 4 weeks.

In the surgery column O means yes, and x means no.

Adverse Effects of CDA-II

Summary of Clinical Efficacy of CDA-II Dr. Kamataro Sano		
http://www.brave-souls.com/learn-from-others/ Home Adverse Effects	<u>cases</u>	<u>%</u>
Vinous irritation	17	34
Vinous thrombosis	4	8